COMMUNIQUÉS West-GlobeNewswire

Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia
13/02/2024
Tonmya™ is a potential new first-line therapy, non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from two Phase 3 trials New Drug Application (NDA) submission to the [...]
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
13/02/2024
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral [...]
Breckenridge Distillery Wins World’s Best Finished Bourbon at 2024 World Whiskies Awards
13/02/2024
Breckenridge Distillery takes home three awards at the 2024 World Whiskies Awards by Whisky Magazine, including World's Best Finished Bourbon, America’s Best Finished Bourbon and Icons of Whisky Campaign Innovator of [...]
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE WESTERN VETERINARY CONFERENCE IN LAS VEGAS, NEVADA
13/02/2024
MINNEAPOLIS, Feb. 13, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for [...]
MANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITY
13/02/2024
San Francisco Fans Nationwide Get Three Free Mangorx ED Pills Based on Sunday’s Game Point Difference Dallas, Texas, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX) (“ MangoRx ” or the “Company”), [...]
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
13/02/2024
-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern Europe in the coming [...]
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
13/02/2024
Phase 3 SOL-1 study will evaluate the efficacy and safety of AXPAXLI in wet AMD BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the [...]
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
13/02/2024
NEEDHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™
13/02/2024
Approval issued by the Health Authority of Colombia INVIMA for Adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) TORONTO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Avicanna [...]
Kraig Biocraft Laboratories Announces New Spider Silk Production Facility in Vietnam's Silk Capital
13/02/2024
ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces it has now taken possession of its new recombinant spider silk production [...]
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
13/02/2024
Redwood City, California to complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE [...]
LianBio Announces Completion of Strategic Review
13/02/2024
LianBio to commence the wind down of its operations, including sale of remaining assets and reduction in force, delisting from Nasdaq and issuance of special cash dividend SHANGHAI, China and PRINCETON, N.J., Feb. 13, [...]
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
13/02/2024
• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage [...]
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
13/02/2024
NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule [...]
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
13/02/2024
BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of [...]
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
13/02/2024
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update. [...]
Augmedix Names Tomer Levy as New Senior Vice President of Engineering
13/02/2024
With deep experience in developing operational efficiency and innovation, Levy will be working to aid Augmedix in scaling its products, accelerating product development, and aligning with the needs of large healthcare [...]
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
13/02/2024
The ABILITY-1 Study is evaluating MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA ® (pembrolizumab) for treatment of patients with advanced solid tumors MDNA11 continues to [...]
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
13/02/2024
Announcement Follows Recent Public Offering and Successful Capital Raising Activity KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its [...]

Pages